Association between brain-derived neurotrophic factor Val66Met gene polymorphism and progressive brain volume changes in schizophrenia

American Journal of Psychiatry

Volumn 164, Issue 12, 2007, Pages 1890-1899

  Ho, Beng Choon ^a   Andreasen, Nancy C ^b   Dawson, Jeffrey D ^b   Wassink, Thomas H ^b  

^a UNIVERSITY OF IOWA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CLOZAPINE; NEUROLEPTIC AGENT; METHIONINE; VALINE;

ARTICLE; BRAIN SIZE; CEREBROSPINAL FLUID; COGNITION; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GRAY MATTER; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE CELL PLASTICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SCHIZOPHRENIA; ADULT; ATROPHY; BRAIN; COGNITIVE DEFECT; COMPARATIVE STUDY; FRONTAL LOBE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENETICS; GENOTYPE; HOSPITALIZATION; LONGITUDINAL STUDY; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; STATISTICS;

ADULT; ANTIPSYCHOTIC AGENTS; ATROPHY; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; COGNITION DISORDERS; FEMALE; FRONTAL LOBE; GENOTYPE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; METHIONINE; NEURONAL PLASTICITY; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, GENETIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; VALINE; VARIATION (GENETICS);

EID: 38449085832     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.2007.05111903     Document Type: Article

References (50)

1. Schulz SC, Koller MM, Kishore PR, Hamer RM, Gehl JJ, Friedel RO: Ventricular enlargement in teenage patients with schizophrenia spectrum disorder. Am J Psychiatry 1983; 140:1592-1595
2. Illowsky BP, Juliano DM, Bigelow LB, Weinberger DR: Stability of CT scan findings in schizophrenia: results of an 8 year follow-up study. J Neurol Neurosurg Psychiatry 1988; 51:209-213
3. DeLisi LE, Sakuma M, Tew W, Kushner M, Hoff AL, Grimson R: Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res 1997; 74:129-140
4. Gur RE, Cowell P, Turetsky BI, Gallacher F, Cannon T, Bilker W, Gur RC: A follow-up magnetic resonance imaging study of schizophrenia. relationship of neuroanatomical changes to clinical and neurobehavioral measures. Arch Gen Psychiatry 1998; 55:145-152
5. Lieberman J, Chakos M, Wu H, Alvir J, Hoffman E, Robinson D, Bilder R: Longitudinal study of brain morphology in first episode schizophrenia. Biol Psychiatry 2001; 49:487-499
6. Mathalon DH, Sullivan EV, Lim KO, Pfefferbaum A: Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Arch Gen Psychiatry 2001; 58:148-157
7. Cahn W, Pol HE, Lems EB, Van Haren NE, Schnack HG, Van Der Linden JA, Schothorst PF, Van Engeland H, Kahn RS: Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Arch Gen Psychiatry 2002; 59:1002-1010
8. Ho BC, Andreasen NC, Nopoulos P, Arndt S, Magnotta V, Flaum M: Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry 2003; 60:585-594
9. Kasai K, Shenton ME, Salisbury DF, Hirayasu Y, Onitsuka T, Spencer MH, Yurgelun-Todd DA, Kikinis R, Jolesz FA, McCarley RW: Progressive decrease of left Heschl gyrus and planum temporale gray matter volume in first-episode schizophrenia: a longitudinal magnetic resonance imaging study. Arch Gen Psychiatry 2003; 60:766-775
10. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, Keefe RSE, Green AI, Gur RE, McEvoy J, Perkins D, Hamer RM, Gu H, Tohen M: Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 2005; 62:361-370
11. Pantelis C, Yucel M, Wood SJ, Velakoulis D, Sun D, Berger G, Lyle Stuart GW, Yung A, Phillips L, McGorry PD: Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophr Bull 2005; 31:672-696
12. Lim KO, Tew W, Kushner M, Chow K, Matsumoto B, DeLisi LE: Cortical gray matter volume deficit in patients with first-episode schizophrenia. Am J Psychiatry 1996; 153:1548-1553
13. Velakoulis D, Wood SJ, Smith DJ, Soulsby B, Brewer W, Leeton L, Desmond P, Suckling J, Bullmore ET, McGuire PK, Pantelis C: Increased duration of illness is associated with reduced volume in right medial temporal/anterior cingulate grey matter in patients with chronic schizophrenia. Schizophr Res 2002; 57:43-49
14. Molina V, Sanz J, Sarramea F, Benito C, Palomo T: Lower prefrontal gray matter volume in schizophrenia in chronic but not in first episode schizophrenia patients. Psychiatry Res 2004; 131:45-56
15. Mathalon DH, Rapoport JL, Davis KL, Krystal JH: Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry (letter). Arch Gen Psychiatry 2003; 60:846-848
16. Weinberger DR, McClure RK: Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: reply (letter). Arch Gen Psychiatry 2003; 60:848-849
17. Gorski JA, Zeiler SR, Tamowski S, Jones KR: Brain-derived neurotrophic factor is required for the maintenance of cortical dendrites. J Neurosci 2003; 23:6856-6865
18. Xu B, Zang K, Ruff NL, Zhang YA, McConnell SK, Stryker MP, Reichardt LF: Cortical degeneration in the absence of neurotrophin signaling: dendritic retraction and neuronal loss after removal of the receptor TrkB. Neuron 2000; 26:233-245
19. Lu B: BDNF and activity-dependent synaptic modulation. Learn Mem 2003; 10:86-98
20. Chen ZY, Patel PD, Sant G, Meng CX, Teng KK, Hempstead BL, Lee FS: Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci 2004; 24:4401-4411
21. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DR: The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112:257-269
22. Ho BC, Milev P, O'Leary DS, Librant A, Andreasen NC, Wassink TH: Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. Arch Gen Psychiatry 2006; 63:731-740
23. Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF, Weinberger DR: Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 2003; 23:6690-6694
24. Pezawas L, Verchinski BA, Mattay VS, Callicott JH, Kolachana BS, Straub RE, Egan MF, Meyer-Lindenberg A, Weinberger DR: The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci 2004; 24:10099-10102
25. Dempster E, Toulopoulou T, McDonald C, Bramon E, Walshe M, Filbey F, Wickham H, Sham PC, Murray RM, Collier DA: Association between BDNF val66 met genotype and episodic memory. Am J Med Genet B Neuropsychiatr Genet 2005; 134:73-75
26. Szeszko PR, Lipsky R, Mentschel C, Robinson D, Gunduz-Bruce H, Sevy S, Ashtari M, Napolitano B, Bilder RM, Kane JM, Goldman D, Malhotra AK: Brain-derived neurotrophic factor Val66met polymorphism and volume of the hippocampal formation. Mol Psychiatry 2005; 10:631-636
27. Agartz I, Sedvall GC, Terenius L, Kulle B, Frigessi A, Hall H, Jonsson EG: BDNF gene variants and brain morphology in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2006; 141:513-523
28. Rattenholl A, Lilie H, Grossmann A, Stern A, Schwarz E, Rudolph R: The pro-sequence facilitates folding of human nerve growth factor from escherichia coli inclusion bodies. Eur J Biochem 2001; 268:3296-3303
29. Huang EJ, Reichardt LF: Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 2001; 24:677-736
30. Lessmann V, Gottmann K, Malcangio M: Neurotrophin secretion: current facts and future prospects. Prog Neurobiol 2003; 69:341-374
31. Dorph-Petersen KA, Pierri JN, Perel JM, Sun Z, Sampson AR, Lewis DA: The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology 2005; 30:1649-1661
32. Konopaske GT, Dorph-Petersen KA, Pierri JN, Wu Q, Sampson AR, Lewis DA: Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys. Neuropsychopharmacology 2007; 32:1216-1223
33. Chakos MH, Shirakawa O, Lieberman J, Lee H, Bilder R, Tamminga CA: Striatal enlargement in rats chronically treated with neuroleptic. Biol Psychiatry 1998; 44:675-684
34. Andersson C, Hamer RM, Lawler CP, Mailman RB, Lieberman JA: Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs. Neuropsychopharmacology 2002; 27:143-151
35. Chakos MH, Lieberman JA, Bilder RM, Borenstein M, Lerner G, Bogerts B, Wu H, Kinon B, Ashtari M: Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatry 1994; 151:1430-1436
36. McCormick L, Decker L, Nopoulos P, Ho BC, Andreasen N: Effects of atypical and typical neuroleptics on anterior cingulate volume in schizophrenia. Schizophr Res 2005; 80:73-84
37. Dazzan P, Morgan KD, Orr K, Hutchinson G, Chitnis X, Suckling J, Fearon P, McGuire PK, Mallett RM, Jones PB, Leff J, Murray RM: Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study. Neuropsychopharmacology 2005; 30:765-774
38. Flaum MA, Andreasen NC, Arndt S: The Iowa Prospective Longitudinal Study of Recent-Onset Psychoses. Schizophr Bull 1992; 18:481-490
39. Andreasen NC, Flaum M, Arndt S: The Comprehensive Assessment of Symptoms and History (CASH): an instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry 1992; 49:615-623
40. Andreasen NC, Rajarethinam R, Cizadlo T, Arndt S, Swayze VW 2nd, Flashman LA, O'Leary DS, Ehrhardt JC, Yuh WT: Automatic atlas-based volume estimation of human brain regions from MR images. J Comput Assist Tomogr 1996; 20:98-106
41. Harris G, Andreasen NC, Cizadlo T, Bailey JM, Bockholt HJ, Magnotta VA, Arndt S: Improving tissue classification in MRI: a three-dimensional multispectral discriminant analysis method with automated training class selection. J Comput Assist Tomogr 1999; 23:144-154
42. Milev P, Ho BC, Arndt S, Andreasen NC: Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005; 162:495-506
43. Saykin AJ, Shtasel DL, Gur RE, Kester DB, Mozley LH, Stafiniak P, Gur RC: Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 1994; 51:124-131
44. Ho BC, Alicata D, Ward J, Moser DJ, O'Leary DS, Arndt S, Andreasen NC: Untreated initial psychosis: relation to cognitive deficits and brain morphology in first-episode schizophrenia. Am J Psychiatry 2003; 160:142-148
45. Davis JM, Kane JM, Marder SR, Brauzer B, Gierl B, Schooler N, Casey DE, Hassan M: Dose response of prophylactic antipsychotics. J Clin Psychiatry 1993; 54(suppl):24-30
46. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223
47. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW: Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 2006; 63:1079-1087
48. Marder SR, Fenton W: Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 2004; 72:5-9
49. Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR: The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006; 32:214-219
50. O'Leary PD, Hughes RA: Design of potent peptide mimetics of brain-derived neurotrophic factor. J Biol Chem 2003; 278:25738-25744